文献速递肺栓塞与肺血管病

雾化与静脉氨甲环酸治疗咯血:一项先导性随机对照试验

Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial.
PubMed 文献 · Chest · 2022-11-19

该先导性随机对照试验纳入110例急诊活动性咯血成人患者,比较雾化氨甲环酸(500 mg tid)与静脉氨甲环酸(500 mg tid)。

核心结论

  • 雾化氨甲环酸可能比静脉给药更有效减少咯血量及急诊介入操作需求。

研究设计与样本

  • 务实、开放标签、随机、平行、单中心先导试验,比较雾化氨甲环酸(500 mg tid)与静脉氨甲环酸(500 mg tid)。
  • 纳入急诊活动性咯血成人患者,每组55例。
  • 排除血流动力学不稳定、需立即介入操作或机械通气的患者。

主要发现

  • 雾化组2例出现无症状支气管痉挛,经短效β受体激动剂雾化后缓解。

关键数值与推荐

  • 雾化氨甲环酸剂量500 mg tid,静脉氨甲环酸剂量500 mg tid。
  • 主要结局为30分钟止血,次要结局包括6、12、24小时咯血量、介入操作及副作用。
  • 出院患者72小时随访期内未接受介入操作或因再出血重返急诊。

临床怎么用

  • 对于急诊活动性咯血且血流动力学稳定的成人患者,雾化氨甲环酸可作为优于静脉给药的止血选择。
  • 雾化给药可能减少支气管动脉栓塞需求并提高急诊离院率。
  • 需注意雾化氨甲环酸可能引起支气管痉挛,必要时用短效β受体激动剂处理。

局限性

  • 先导性单中心试验,样本量小(每组55例),结论需未来更大规模研究验证。
  • 开放标签设计可能引入偏倚。
  • 排除血流动力学不稳定、需立即介入或机械通气的患者,适用人群有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TA) is used to control bleeding in patients with hemoptysis. However, the effectiveness of the different routes of TA administration has not been studied. RESEARCH QUESTION: Does the nebulized route of TA administration reduce the amount of hemoptysis compared with the IV route in patients presenting to the ED with hemoptysis? STUDY DESIGN AND METHODS: This was a pragmatic, open-label, randomized, parallel, single-center, pilot trial of nebulized TA (500 mg tid) vs IV TA (500 mg tid) in adult patients presenting to the ED with active hemoptysis. The primary outcome was cessation of bleeding at 30 min. Secondary outcomes included amount of hemoptysis at 6, 12, and 24 h; interventional procedures; and side effects of TA. Patients who were hemodynamically unstable or requiring immediate interventional procedure or mechanical ventilation were excluded from the study. RESULTS: Of the 55 patients in each arm, hemoptysis cessation at 30 min following TA administration was significantly higher in the nebulization arm (n = 40) compared with the IV arm (n = 28): χ2 (1, n = 110) = 5.55; P = .0019. Also, hemoptysis amount was reduced significantly in the nebulization arm at all time periods of observation (P value at 30 min = .011, at 6 h = .002, 12 h = .0008, and at 24 h = .005). Fewer patients in the nebulization arm required bronchial artery embolization (13 vs 21; P = .024) and thereby had higher discharge rates from the ED (67.92% vs 39.02%; P = .005). Two patients in the nebulization arm had asymptomatic bronchoconstriction that resolved after short-acting beta-agonist nebulization. No patient discharged from the ED underwent any interventional procedure or revisited the ED with rebleed during the 72 h follow-up period. INTERPRETATION: Nebulized TA may be more efficacious than IV TA in reducing the amount of hemoptysis and need for ED interventional procedures. Future larger studies are needed to further explore the potential of nebulized TA compared with IV TA in patients with mild hemoptysis. CLINICAL TRIAL REGISTRATION: Clinical Trials Registry-India; No.: CTRI/2019/05/019337; URL: http://ctri.nic.in/Clinicaltrials/advancesearchmain.php.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Gopinath B, Mishra PR, Aggarwal P, et al. Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial. Chest. 2022. PMID: 36410494. doi:10.1016/j.chest.2022.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。